American Association for Cancer Research
21598290cd140377-sup-tab3.pdf (129.08 kB)

Supplementary Table 3 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions

Download (129.08 kB)
journal contribution
posted on 2023-04-03, 20:45 authored by Christine M. Lovly, Abha Gupta, Doron Lipson, Geoff Otto, Tina Brennan, Catherine T. Chung, Scott C. Borinstein, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Cheryl M. Coffin

PDF file - 137KB, Summary of genomic coordinates for the kinase fusions identified in this study. The sample number is depicted in the far left column. For tumor samples in which a kinase fusion was identified, the genomic coordinates for of each of the fusion genes is indicated. There were no other recurrent alterations. *The FN1-ALK fusion was detected with RNA sequencing. #Sufficient material was available to verify these kinase fusions with RNA sequencing.



Inflammatory myofibroblastic tumor (IMT) is a neoplasm that typically occurs in children. The genetic landscape of this tumor is incompletely understood and therapeutic options are limited. Although 50% of IMTs harbor anaplastic lymphoma kinase (ALK) rearrangements, no therapeutic targets have been identified in ALK-negative tumors. We report for the first time that IMTs harbor other actionable targets, including ROS1 and PDGFRβ fusions. We detail the case of an 8-year-old boy with treatment-refractory ALK-negative IMT. Molecular tumor profiling revealed a ROS1 fusion, and he had a dramatic response to the ROS1 inhibitor crizotinib. This case prompted assessment of a larger series of IMTs. Next-generation sequencing revealed that 85% of cases evaluated harbored kinase fusions involving ALK, ROS1, or PDGFRβ. Our study represents the most comprehensive genetic analysis of IMTs to date and also provides a rationale for routine molecular profiling of these tumors to detect therapeutically actionable kinase fusions.Significance: Our study describes the most comprehensive genomics-based evaluation of IMT to date. Because there is no “standard-of-care” therapy for IMT, the identification of actionable genomic alterations, in addition to ALK, is expected to redefine management strategies for patients with this disease. Cancer Discov; 4(8); 889–95. ©2014 AACR.See related commentary by Le and Doebele, p. 870This article is highlighted in the In This Issue feature, p. 855